A Cost-Consequences analysis of the effect of Pregabalin in the treatment of peripheral Neuropathic Pain in routine medical practice in Primary Care settings

Navarro, Ana; Saldaña, María T.; Pérez, Concepción; Torrades, Sandra; Rejas, Javier

doi:10.1186/1471-2377-11-7

Cited by 35 publications

(25 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Estudios han señalado que son las consultas con profesionales de la salud, particularmente especialistas, las responsables de la mayor parte de los costes directos debidos al dolor crónico (21). En este sentido, varios autores han señalado que la reducción del dolor, mediante el uso de medicamentos y terapias/ dosis adecuadas, se asocia a una reducción de la utilización de recursos sanitarios, en especial de las visitas realizadas (26)(27)(28).…”

Section: Costes Directosunclassified

“…Resultados del Pain Proposal (5) mostraron que los europeos con dolor crónico están de baja una media de 14 días al año a causa de su enfermedad. Esta cifra es muy inferior a las mostradas por diversos estudios observacionales en pacientes con dolor neuropático, en especial si se trata de radiculopatías cervicales/lumbares, donde se observaron de media más de 20 días de baja en el periodo de estudio de 12 semanas (27,28).…”

Section: Costes Indirectosunclassified

See 1 more Smart Citation

Situación actual del dolor crónico en España: iniciativa "Pain Proposal"

Torralba¹,

Miquel

Darbà

2014

Rev. Soc. Esp. Dolor

View full text Add to dashboard Cite

Recibido: 25-09-12. Aceptado: 01-12-12.Financiación: La iniciativa Pain Proposal fue promovida y avalada por la Federación Europea de la Asociación Internacional del Estudio del Dolor (EFIC) y la Federación Europea de Asociaciones Neurológicas (EFNA). Pfizer financió la parte logística de la iniciativa. La elaboración del manuscrito ha contado con la colaboración de Esther Tapia, medical writer freelance, cuyos honorarios han sido financiados por Pfizer. ABSTRACTOne in five Europeans (19 %) is estimated to suffer from chronic pain.The Pain Proposal initiative represents perspectives from a range of stakeholders from across 15 European countries concerning chronic pain, including people with chronic pain, clinicians from different medical specialties, policy experts, industry members and health economists. This article sets forth the recommendations and opinions of the Pain Proposal in reference to the present chronic pain care model in Spain.The data presented in this report have highlighted a number of inadequacies in the way chronic pain is currently managed in Spain. Patients have reported long waiting times for referral and persisting pain despite treatment, with consequences for their ability to work and their relationships with partners and family.Healthcare professionals have also reported dissatisfaction with aspects of chronic pain management and a desire for greater support.Improving pain management will bring substantial economic benefits: More efficient use of existing resources for pain management, less absenteeism, greater productivity, and a reduced burden on social security budgets.Everyone involved in the chronic pain area, from healthcare professionals to government departments, needs to work together to improve pain management across Spain.Key words: Chronic pain. Survey. Impact of pain. Cost of illness. RESUMENSe estima que uno de cada seis españoles (17 %) sufre de dolor crónico. La iniciativa Pain Proposal agrupó la visión de diferentes sectores involucrados en el dolor crónico procedentes de 15 países europeos, que incluyó personas con dolor crónico, diferentes especialistas médicos gestores, decisores sanitarios y economistas de la salud. En este artículo se muestran las directrices y opiniones del Pain Proposal referidas al modelo actual de atención del dolor crónico en España.Los datos presentados en este informe han puesto de relieve una serie de deficiencias en el manejo del dolor crónico actualmente en España. Los pacientes se quejaron del largo periodo de tiempo de espera para el diagnóstico y del dolor persistente a pesar del tratamiento, lo cual afectaba a su capacidad laboral y a sus relaciones socio-familiares. Profesionales de la salud manifestaron también insatisfacción con diferentes aspectos del manejo del dolor crónico. La mejora de la gestión de dolor proporcionaría beneficios económicos sustanciales: un uso más eficiente de los recursos existentes para el tratamiento del dolor, menor absentismo, una mayor productividad y una menor carga sobre los presupuestos de la Segur...

show abstract

Section: Costes Directosunclassified

Section: Costes Indirectosunclassified

Situación actual del dolor crónico en España: iniciativa "Pain Proposal"

Torralba¹,

Miquel

Darbà

2014

Rev. Soc. Esp. Dolor

View full text Add to dashboard Cite

show abstract

“…Managing patients with PNP is challenging (Dworkin et al., 2007, 2010; Finnerup et al., 2010; Finnerup, Attal et al ., 2015); it often becomes chronic, with marked long‐term reductions in health‐related quality of life (HRQOL) (O'Connor, 2009), decreased individual productivity and increased patient and healthcare expenditure (Rodríguez et al., 2007; Navarro et al., 2011). Aetiologies range from mechanical and inflammatory diseases to injury and nerve compression (Hall et al., 2006).…”

Section: Introductionmentioning

confidence: 99%

Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain

Haanpää

Cruccu

Nurmikko

et al. 2015

European Journal of Pain

View full text Add to dashboard Cite

BackgroundClinical trials have not yet compared the efficacy of capsaicin 8% patch with current standard therapy in peripheral neuropathic pain (PNP).ObjectivesHead‐to‐head efficacy and safety trial comparing the capsaicin patch with pregabalin in PNP.MethodsOpen‐label, randomized, multicentre, non‐inferiority trial. Patients with PNP, aged 18–80 years, were randomly assigned to either the capsaicin 8% patch (n = 282) or an optimised dose of oral pregabalin (n = 277), and assessed for a ≥30% mean decrease in Numeric Pain Rating Scale (NPRS) score from baseline to Week 8. Secondary endpoints included optimal therapeutic effect (OTE), time‐to‐onset of pain relief and treatment satisfaction.ResultsThe capsaicin 8% patch was non‐inferior to pregabalin in achievement of a ≥30% mean decrease in NPRS score from baseline to Week 8 (55.7% vs. 54.5%, respectively; Odds ratio: 1.03 [95% CI: 0.72, 1.50]). The proportion of patients achieving OTE at Week 8 was 52.1% for the capsaicin 8% patch versus 44.8% for pregabalin (difference: 7.3%; 95% CI: −0.9%, 15.6%). The median time‐to‐onset of pain relief was significantly shorter for capsaicin 8% patch versus pregabalin (7.5 vs. 36.0 days; Hazard ratio: 1.68 [95% CI: 1.35, 2.08]; p < 0.0001). Treatment satisfaction was also significantly greater with the capsaicin 8% patch versus pregabalin. TEAEs were mild‐to‐moderate in severity, and resulted in treatment discontinuation only with pregabalin (n = 24). Systemic adverse drug reactions ranged from 0 to 1.1% with capsaicin 8% patch and 2.5 to 18.4% with pregabalin.ConclusionsThe capsaicin 8% patch provided non‐inferior pain relief to an optimized dose of pregabalin in PNP, with a faster onset of action, fewer systemic side effects and greater treatment satisfaction.

show abstract

“…21 Therefore, it is plausible that pain intensity acts as a predictor of cost and resource utilization in patients with PNP. Our objective in the present study was to model the association and predictive value of pain intensity on both health care and nonhealth care cost and resource utilization in patients with chronic PNP treated in routine clinical practice settings in Spain.…”

mentioning

confidence: 99%